San Diego, California headquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35 with a total trading volume of 187,480 shares. The Company's shares have advanced 4.44% on an YTD basis. The stock is trading below its 50-day moving average by 7.06%. Furthermore, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the US, have a Relative Strength Index (RSI) of 44.96.
On December 06th, 2016, Regulus Therapeutics announced two new drug development candidates. The first candidate, RGLS5040, is an anti-miR targeting microRNA-27 for the treatment of cholestatic diseases. The second candidate, RGLS4326, is an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease. The free research report on RGLS is available at:
Shares in Dallas, Texas-based Abeona Therapeutics Inc. ended at $5.00, down 1.96% from the last trading session. The stock recorded a trading volume of 343,791 shares. The Company's shares have gained 11.11% in the last one month and 3.09% since the start of this year. The stock is trading 14.38% above its 200-day moving average. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 40.51.
On January 06th, 2017, research firm Jefferies initiated a 'Buy' rating on the Company's stock.
On January 19th, 2017, Abeona Therapeutics announced that the European Medicines Agency Committee for Orphan Medicinal Products has granted Orphan Drug Designation for Abeona's gene therapy program ABO-101 for children impacted by Sanfilippo syndrome type B (MPS IIIB), a rare autosomal recessive disease that causes neurocognitive decline, speech loss, loss of mobility, and premature death in children. ABO-101 has previously been granted the FDA Orphan Product Designation in the US and received the Rare Pediatric Disease Designation as a pre-requisite part of the FDA's Priority Review Voucher process. The FDA has allowed the Investigational New Drug for a Phase-1/2 clinical trial. The complimentary report on ABEO can be downloaded at:
George Town, the Cayman Islands-based Theravance Biopharma Inc.'s stock ended yesterday's session 2.47% lower at $31.19 with a total trading volume of 121,298 shares. The Company's shares have advanced 2.06% in the previous three months. The stock is trading 0.31% above its 50-day moving average and 14.67% above its 200-day moving average. Additionally, shares of Theravance Biopharma, which discovers, develops, and commercializes human therapeutics, have an RSI of 42.77.
On December 21st, 2016, research firm Needham initiated a 'Buy' rating on the Company's stock, with a target price of $40 per share.
On January 17th, 2017, Theravance announced that new interim data from its ongoing Telavancin Observational Use Registry (TOUR™) study will be the focus of an oral presentation at the Society of Critical Care Medicine's (SCCM) 46th Critical Care Congress. TOUR is designed to assess how VIBATIV® is being used by healthcare practitioners to treat patients in real-world clinical settings. The SCCM 46th Critical Care Congress is being held in Honolulu, HI on January 20th-25th, 2017. Visit us today and download our complete research report on TBPH for free at:
At the close on Thursday, shares in Cambridge, Massachusetts headquartered Sage Therapeutics Inc. recorded a trading volume of 229,249 shares. The stock finished 1.32% lower at $53.03. The Company's shares have gained 9.34% in the last one month, 28.93% in the previous three months, and 3.86% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.00% and 28.88%, respectively. Furthermore, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 54.17.
On December 19th, 2016, Sage Therapeutics announced the initiation of Phase-2 clinical development for SAGE-217, a novel, internally-developed, next generation oral GABAA receptor modulator, in two mood disorder clinical programs - postpartum depression (PPD) and major depressive disorder (MDD). Top-line results from the Part A open-label study in MDD is expected in H1 2017, and the PPD study is anticipated to report results in H2 2017. Get free access to your technical report on SAGE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA